On Tuesday, Replimune Group Inc (NASDAQ: REPL) opened lower -3.31% from the last session, before settling in for the closing price of $9.83. Price fluctuations for REPL have ranged from $6.44 to $17.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 4.64% at the time writing. With a float of $62.53 million, this company’s outstanding shares have now reached $77.09 million.
In an organization with 479 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Replimune Group Inc (REPL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Replimune Group Inc is 18.88%, while institutional ownership is 94.55%. The most recent insider transaction that took place on May 20 ’25, was worth 260,169. In this transaction Director of this company sold 32,279 shares at a rate of $8.06, taking the stock ownership to the 1,405,071 shares. Before that another transaction happened on May 20 ’25, when Company’s Chief Medical Officer sold 7,952 for $8.06, making the entire transaction worth $64,093. This insider now owns 146,933 shares in total.
Replimune Group Inc (REPL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 4.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.63% during the next five years compared to -14.85% drop over the previous five years of trading.
Replimune Group Inc (NASDAQ: REPL) Trading Performance Indicators
Check out the current performance indicators for Replimune Group Inc (REPL). In the past quarter, the stock posted a quick ratio of 7.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.21, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -2.07 in one year’s time.
Technical Analysis of Replimune Group Inc (REPL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.91 million. That was inferior than the volume of 0.96 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.10%. Additionally, its Average True Range was 0.71.
During the past 100 days, Replimune Group Inc’s (REPL) raw stochastic average was set at 36.68%, which indicates a significant decrease from 49.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.20% in the past 14 days, which was lower than the 80.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.67, while its 200-day Moving Average is $11.11. However, in the short run, Replimune Group Inc’s stock first resistance to watch stands at $9.89. Second resistance stands at $10.28. The third major resistance level sits at $10.48. If the price goes on to break the first support level at $9.31, it is likely to go to the next support level at $9.11. The third support level lies at $8.72 if the price breaches the second support level.
Replimune Group Inc (NASDAQ: REPL) Key Stats
There are currently 77,087K shares outstanding in the company with a market cap of 732.71 million. Presently, the company’s annual sales total 0 K according to its annual income of -247,300 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -74,130 K.
